Researchers say a woman struggling with obesity who couldn't resist eating fatty foods experienced declines in her cravings after taking tirzepatide, the GLP-1 weight-loss drug used in Mounjaro and Zepbound.
Studies of the woman's brain function suggest the drug quieted what the researchers call "food noise" -- brain activity tied to out-of-control food cravings.
However, these drug-linked interruptions in food noise wore off after a few months, suggesting that tirzepatide is not a permanent solution to conditions such as binge eating.
"Although this study only featured the data from one person taking tirzepatide, it provides compelling data about how GLP-1 and GIP inhibitors alter electrical signals in the brain," said study co-first author Wonkyung Choi, a PhD candidate at the University of Pennsylvania School of Medicine in Philadelphia.
Related
